Characteristics of studies on the effect of AT-II on the T/N ratio in patients with hepatic malignancies.

<p>Abbreviations: HCC = Hepatocellular Carcinoma. CRLM = Colorectal Liver Metastases. UP = Metastases of an Unknown Primary. PCLM = Pancreatic Cancer Liver Metastases. NA = Not Available. RA = radioactivity. SPECT = Single-Photon Emission Computed Tomography. HAPS = Hepatic Arterial Perfusion Scintigraphy. PET = Positron Emission Tomography. ^81mKr = Krypton-81m. ¹³¹I = Iodine-131. ^99mTc MSA = Radiolabeled albumin microspheres. ⁶²Cu-PTSM = copper-pyruvaldehyde-bis (N4-methylthiosemicarbazone).</p

T/N ratios before, during and after AT-II infusion, and T/N ratio improvement factors in patients with hepatic malignancies.

<p>T/N ratios are described as median (range). P-values correspond to reported significance levels of Wilcoxon test for paired data. *The first p-value refers to the improvement of T/N ratio during infusion and the last to post-infusion. Abbreviations: NR = Not Reported.</p

Patient dosimetry.

<p>The mean dose (Gy) in the low-dose ROI (LD) and the high-dose ROI (HD) are given for all patients.</p

Search Syntax.

<p>In this table, the search syntax used in PubMed, EMBASE and Cochrane databases is displayed. The number of results include double titles. In total, 524 original titles were identified.</p

Quality assessment of selected studies.

<p>Abbreviations: Y = Yes, N = No.</p

Visualization of the visibility and unique detectability results.

<p>The activity concentration in the hot spheres was 2.4 MBq ml⁻¹ for both the images without (rows 1–3) and with background activity (rows 4–6). In the 1^st and 4^th row, the SPECT+PSF (1^st and 3^rd column) and PET+PSF+TOF (2^nd and 4^th column) slices are overlaid with the location of the visible phantom spheres (red). In rows 2, 3, 5 and 6 a background slice is overlaid with the location of false positive regions. For illustrative reasons, only the largest false positive ROIs are shown (red: 10 mm; green: 13 mm; blue: 17 mm; yellow: 22 mm; purple: 37 mm). Clustered ROIs with connecting center voxels are represented by the ROI with the highest υ_TEST-FP value.</p

Phantom dosimetry.

<p>The uncorrected mean dose (Gy) in the 6 hot sphere ROIs and the background ROI (BKG), followed by the mean dose corrected for PVE in brackets (spheres only). The TRUE dose represents the actual dose in the phantom.</p

Flowchart of study design.

<p>IIA = Internal Iliac Artery. CIA = Common Iliac Artery. EIA = External Iliac Artery.</p

Phantom experiments.

<p>Phantom experiments.</p

Patient and treatment characteristics.

a<p>Primary disease: CRC = colorectal carcinoma; NPC = nasopharyngeal carcinoma; MC = mammary carcinoma; HCC = hepatocellular carcinoma.</p>b<p>Lobes treated: W = whole liver treatment; L = left lobar treatment.</p>c<p>V_L = treated liver volume (ml).</p>d<p>V_T = volume of tumours in treated liver volume (ml).</p>e<p>A_A = Activity administered to the patient, at time of administration (MBq).</p>f<p>A_S = Activity at time of SPECT acquisition (MBq).</p>g<p>A_P = Activity at time of PET acquisition (MBq).</p